1Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors[J]. Int J Radiat Oncol Biol Phys,2004,58(3) :903-913.
2Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non- small cell lung cancer: a randomized trial[J]. JAMA, 2003,290(16):2149 - 2158.
3Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774) [J]. Adv Exp Med Biol, 2003,532 : 235-246.
4Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer[J]. Oncologist, 2002,7( Suppl 4) :9-15.
5Chakravarti A, Loeffler JS, Dyson NJ, et al. Insulin-like growth factor receptor Ⅰ mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling[J]. Cancer Res, 2002,62 (1) : 200-207.
6Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-Ⅰ receptor signaling and acquired resistance to gefitinih (ZD1839; Iressa) in human breast and prostate cancer cells [J]. Endocrine-Related Cancer,2004,11 (4) : 793-814.
7Camirand A,Zakikhani M, Young F, et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells[J]. Breast Cancer Res, 2005,7 (4) : R570- 579.
8Cappuzzo F, Toschi L, Tallini G, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib[J]. Annals of Oncology, 2006, 17(7) : 1120-1127.
9Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J]. Clinical Cancer Res, 2004,10(2): 784-793.
10Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models[J]. Cancer Science, 2004,95(12) :984-989.